The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
798
August 11, 1989
View Complete Issue         Table of Contents 2019 
Topical Metronidazole For Rosacea
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Topical Metronidazole For Rosacea
August 11, 1989 (Issue: 798)
A topical formulation of 0.75% metronidazole gel (MetroGel - Curatek), an antibacterial, antiparasitic agent, was recently approved by the US Food and Drug Administration for treatment of rosacea.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Topical Metronidazole For Rosacea
Article code: 798b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.